Use of monoclonal antibodies to tumor necrosis factor (the drug remicade) in rheumatoid arthritis: pilot results


Cite item

Full Text

Abstract

Aim. To study effectiveness and tolerance of monoclonal antibodies to tumor necrosis factor (the drug remicade) in patients with rheumatoid arthritis (RA).
Material and methods. Remicade treatment results are considered for 25 RA patients receiving methotrexate the activity of which was inadequate for these patients. Remicade was infused intravenously in a dose 200 mg 4 times for 22 weeks.
Results. Remicade produced positive clinical and laboratory effects as early as the first infusion. The response was observed during 22 weeks of the treatment in 17 of 25 patients. Remicade tolerance was good. One patient failed the treatment because of development of collapse.
Conclusion. Pilot results of remicade trial point to its high therapeutic potential and perspectives in rheumatology.

References

  1. Harris Е. D. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 1990; 322: 1277-1289.
  2. Lee D. M., Weinblatl M. E. Rheumatoid arthritis. Lancet 2001; 358; 903-911.
  3. Pinctis Т., Callahan L. F. The "side effects" of rheumatoid arthritis; joint destruction, disability, and earle mortality. Br. J. Rheumatol. 1993; 32 (stippl. 1): 28-37.
  4. Сигидин Я. А., Лукина Г. В. Базисная (патогенетическая) терапия ревматоидного артрита. М.: Ноиартис; 2000.
  5. Насонов Е. Л. Противовоспалительная терапия ревматических болезней. М.: Изд-во "М-СИТИ"; 1996.
  6. El-Gabay H. D., Lipsky P. E. Why do we not have a cure for rheumatoid arthritis. Arthr. Res. 2002; 4 (suppl. 3): S297-S301.
  7. Насонов Е. Л. Ревматоидный артрит: терапевтические проблемы. Врач 1999; 5: 7-20.
  8. Beutler В. A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (suppl. 57): 16-21.
  9. Dinarello C. A., Moldawer L. L. Proinflamatory and anti-inflammatory cytokines in rheumatoid arthritis. A primer for clinicians. 3-rd ed. Amgen Inc.; 2002. 11
  10. Feldman M., Brennan F., Maini R. N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397-440.
  11. Chou E. H. S., Panyi G. S. Cytokine pathway and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 200Г 344906-916.
  12. Насонов Е. Л. Фактор некроза опухоли альфа - новая мишень для противовоспалительной терапии ревматоидного артрита. Клин, фармакол. тер. 2001; 1: 64-70.
  13. Насонов Е. Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли. Рус. мед. журн. 2001; 9 (7- 8): 280-284.
  14. Markham A., Lamb H. М. Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: J341 - 1359.
  15. Maini R., Breedvald F. C., Kalden J. R. et al. Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor alpha antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthr. and Rheum., 1998; 41: 1552-1563.
  16. Maini R., St. Clair E. W., Breedvald F. et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354: 1932-1939.
  17. Smolen J., Schaiber Т., DeWoody K. et al. Long-term followup of patients treated with infliximab (anti-TNF-alpha antibody) in clinical trials. Ann. Rheum. Dis. 2000; 59 (suppl. 1): 164.
  18. Kavanaugh A., St. Clair E. W., McCttne W. J. et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumathol. 2000; 27: 841-850.
  19. Lipsky P. E., van der Heijde D. M., St. Clair E. W. et al. Infliximab and methotrexate in the rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594-1602.
  20. Emery P., Reginster J.-Y., Appelboom T. et al. WHO collaborative Centre consensus meetintg on anti-cytokine therapy in rheumatoid arthritis. Rheumatology 2000; 40: 699-702.
  21. Arnett F. C., Edworth S. M., Bloch D. A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr. and Rheum. 1988; 31: 315-324.
  22. Ritchie D. M., Boyle J. A., Mclnnes J. M. et al. Clinical studies with an articular index for assessment of joint tenderness in patients with rheumatoid arthritis. Quart. J. Med. 1968; 37: 393-406.
  23. Fries J. F., Spitz P. W., Young D. Y. The dimension of health outcomes: the Health Assessment Questionnaire, Disability Pain Scale. J. Rheumatol. 1982; 9: 789-793.
  24. Van der Heijde D. M., van 't Hof M. A., van Riel P. L. С. М. et al. Validity of single variable and composite indices for measuring disease activity in rheumatoid arthritis. Ann. Rheum. Dis. 1992; 51: 177-181.
  25. Чичасова Н. В., Насонова М. Б., Степапец О. В., Насонов Е. Л. Современные подходы к оценке активности ревматоидного артрита. Тер. арх. 2002; 5: 57-60.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies